These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16407541)

  • 1. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2.
    Smith PD; Mount MP; Shree R; Callaghan S; Slack RS; Anisman H; Vincent I; Wang X; Mao Z; Park DS
    J Neurosci; 2006 Jan; 26(2):440-7. PubMed ID: 16407541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Mount MP; Zhang Y; Amini M; Callaghan S; Kulczycki J; Mao Z; Slack RS; Anisman H; Park DS
    J Biol Chem; 2013 May; 288(20):14362-14371. PubMed ID: 23536182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdk5/p25 specific inhibitory peptide TFP5 rescues the loss of dopaminergic neurons in a sub-acute MPTP induced PD mouse model.
    Zhang Q; Xie H; Ji Z; He R; Xu M; He Y; Huang J; Pan S; Hu Y
    Neurosci Lett; 2016 Oct; 632():1-7. PubMed ID: 27542341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
    Kanagaraj N; Beiping H; Dheen ST; Tay SS
    Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
    Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
    FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.
    Yao L; Li W; She H; Dou J; Jia L; He Y; Yang Q; Zhu J; Cápiro NL; Walker DI; Pennell KD; Pang Y; Liu Y; Han Y; Mao Z
    J Biol Chem; 2012 Oct; 287(41):34246-55. PubMed ID: 22891246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
    Hisanaga S; Saito T
    Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
    Binukumar BK; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
    Mol Biol Cell; 2015 Dec; 26(24):4478-91. PubMed ID: 26399293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease.
    Qu D; Rashidian J; Mount MP; Aleyasin H; Parsanejad M; Lira A; Haque E; Zhang Y; Callaghan S; Daigle M; Rousseaux MW; Slack RS; Albert PR; Vincent I; Woulfe JM; Park DS
    Neuron; 2007 Jul; 55(1):37-52. PubMed ID: 17610816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2.
    Tang X; Wang X; Gong X; Tong M; Park D; Xia Z; Mao Z
    J Neurosci; 2005 May; 25(19):4823-34. PubMed ID: 15888658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.
    Paoletti P; Vila I; Rifé M; Lizcano JM; Alberch J; Ginés S
    J Neurosci; 2008 Oct; 28(40):10090-101. PubMed ID: 18829967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation.
    Kamei H; Saito T; Ozawa M; Fujita Y; Asada A; Bibb JA; Saido TC; Sorimachi H; Hisanaga S
    J Biol Chem; 2007 Jan; 282(3):1687-94. PubMed ID: 17121855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calpain-2/p35-p25/Cdk5 pathway is involved in the neuronal apoptosis induced by polybrominated diphenyl ether-153.
    Zhang H; Chang L; Zhang H; Nie J; Zhang Z; Yang X; Vuong AM; Wang Z; Chen A; Niu Q
    Toxicol Lett; 2017 Aug; 277():41-53. PubMed ID: 28559121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease.
    Crocker SJ; Smith PD; Jackson-Lewis V; Lamba WR; Hayley SP; Grimm E; Callaghan SM; Slack RS; Melloni E; Przedborski S; Robertson GS; Anisman H; Merali Z; Park DS
    J Neurosci; 2003 May; 23(10):4081-91. PubMed ID: 12764095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK5 contributes to neuronal apoptosis via promoting MEF2D phosphorylation in rat model of intracerebral hemorrhage.
    Ke K; Shen J; Song Y; Cao M; Lu H; Liu C; Shen J; Li A; Huang J; Ni H; Chen X; Liu Y
    J Mol Neurosci; 2015 May; 56(1):48-59. PubMed ID: 25417143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells.
    Nath R; Davis M; Probert AW; Kupina NC; Ren X; Schielke GP; Wang KK
    Biochem Biophys Res Commun; 2000 Jul; 274(1):16-21. PubMed ID: 10903889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B.
    Guo B; Hu S; Zheng C; Wang H; Luo F; Li H; Cui W; Yang X; Cui G; Mak S; Choi TC; Ma ED; Wang Y; Lee SMY; Zhang Z; Han Y
    Neuropharmacology; 2017 Nov; 126():12-24. PubMed ID: 28807675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease.
    Binukumar BK; Pant HC
    Neural Regen Res; 2016 May; 11(5):698-701. PubMed ID: 27335538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.